Program Announcement for the Defense Health Agency

Amyotrophic Lateral Sclerosis Research Program

Therapeutic Idea Award

Funding Opportunity Number: HT942526ALSRPTIA

Pre-Application Due: June 24, 2026

Application Due: September 30, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click**  **to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, ***the strength of the application should rely on the approach.***

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $10.08 million (M) to fund approximately 12 Therapeutic Idea Award applications with total cost caps of $840,000 per award. The maximum period of performance is two years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), June 24, 2026
- **Invitation to Submit an Application:** August 3, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 30, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, October 6, 2026
- **Peer Review:** November 2026
- **Programmatic Review:** January 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526ALSRPTIA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status. An investigator may be named as PI on no more than three FY26 ALSRP applications across all award mechanisms, in any combination.

For titles outside of academia that may not be analogous to traditional hierarchies, investigators at or above an independent scientist level may be named by their organization as the PI on the application.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Amyotrophic Lateral Sclerosis Research Program (ALSRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the ALSRP in 2007 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the ALSRP from FY07 through FY25 totaled $309.4M. The FY26 appropriation is $40.0M.

The Vision of the FY26 ALSRP is to improve outcomes and find cures for people with ALS. The Mission is to fund and accelerate research that translates science into effective ALS treatments. The program will prioritize applications that support the vision and mission of the FY26 ALSRP.

3.1. Award History

The ALSRP Therapeutic Idea Award mechanism was first offered in FY10. Since then, 769 Therapeutic Idea Award applications were received, and 179 were recommended for funding.

3.2. Intent of the Therapeutic Idea Award

The FY26 ALSRP Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

The FY26 ALSRP TIA welcomes medical device studies as well as investigational drug studies.

Projects that focus primarily on pathophysiology of ALS without development of a therapy or device are outside the scope of this funding opportunity.

Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, ***the strength of the application should rely on the approach.***

3.2.1. Key Elements for the TIA

The key elements of this award mechanism are:

- **Innovation:** The proposed project should represent the exploration of a highly innovative, untested, potentially high-gain concept, theory, paradigm, and/or method(s) that may lead to future therapeutics for ALS.
- **Impact:** Research submitted for consideration for the FY26 TIA may address a specific ALS subtype and does not have to broadly apply to all patients. Research should be non-incremental and pioneer transformative results that could lay the foundation for a new direction in the field of ALS therapy development. **Incremental advancement of ongoing research does not meet the intent of this funding opportunity.**

- **Strong Scientific Rationale:** Projects must include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality.
- **Biomarkers:** Applicants are required to include rational development of a biomarker(s) to measure biological effects of the study compound or modality for eventual clinical trials.
    - Biomarkers should be **specific to the therapeutic strategy's biological mechanism** and may include:
        - Target engagement biomarkers
        - Objective pharmacodynamic biomarkers to measure the biological effect of the investigational therapeutic
        - Predictive/cohort-selective biomarkers to identify patients (including individual, subgroup, or pre-symptomatic gene carriers) likely to benefit
    - Applications focused solely on developing diagnosis, prognosis, or disease progression biomarkers, without a clear link to therapeutic development, will not be supported. Researchers pursuing such studies are encouraged to apply for the Clinical Outcomes and Biomarkers Award (HT942525ALSRPCOBA).

Applicants are encouraged to consult the following resources for additional information regarding biomarker types, qualifications, and use in ALS clinical trials:

- "National Institute of Neurological Disorders and Stroke (NINDS) Biomarker Program," National Institutes of Health (NIH) https://www.ninds.nih.gov/current-research/focus-tools-topics/focus-biomarkers-research
- "U.S. Food and Drug Administration (FDA) Biomarker Qualification Program," FDA, https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program.
- FDA-NIH Biomarker Working Group, *BEST (Biomarkers, EndpointS, and other Tools) Resource* (U.S. Food and Drug Administration, 2016+), https://www.ncbi.nlm.nih.gov/books/NBK326791/.
- FDA Center for Drug Evaluation and Research, *Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry* (FDA, 2019), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry.
- Leonard H van den Berg et al, "Revised Airlie House Consensus Guidelines for Design and Implementation of ALS Clinical Trials," *Neurology* 92, no. 14 (2019): e1610-e1623, https://pubmed.ncbi.nlm.nih.gov/30850440/.
- Nick S. Verber et al, "Biomarkers in Motor Neuron Disease: A State of the Art Review," *Frontiers in Neurology* 10 (2019): 291, https://www.frontiersin.org/articles/10.3389/fneur.2019.00291/full.
- Michael Benatar et al, "ALS Biomarkers for Therapy Development: State of the Field and Future Directions," *Muscle Nerve* 53, no. 2 (2016): 169-182, https://doi.org/10.1002/mus.24979.

Expected Outcomes: Projects should strive to produce the type and amount of data needed to apply for the next stage of therapy development, i.e., ALSRP Therapeutic Development Award or other mechanisms for ALS therapeutic advancement.

3.2.2. Other Important Considerations for the TIA

The ALSRP aims to improve the health, care, and well-being of military Service Members, Veterans, their families, and the American public affected by ALS. Evidence from scientific research suggests a mutually inclusive relationship between ALS and military service, with a higher rate of incidence in the Veteran population, without any known reasons for this incidence. Knowledge, information, products, or technologies gained from the proposed research should advance research that is of significance to Service Members, Veterans, and/or their Families.

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Standards for Preclinical Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines. Projects that include research on animal models are required to submit Attachment 9, Animal Research Plan, as part of the application package to describe how these standards will be addressed.

Guidelines for the Use of ALS Animal Models: Many factors must be considered in the design of studies using animal models of ALS. A number of investigators and organizations have published guidelines and recommendations for the design of ALS animal model studies. Applicants are strongly encouraged to become familiar with the concepts presented in the articles listed below and to incorporate recommendations contained therein in their study designs. While most of the recommendations pertain to the SOD1-G93A transgenic mouse model, many general concepts for using animal models for ALS research are also described.

- Albert C. Ludolph et al, “Guidelines for Preclinical Animal Research in ALS/MND: A Consensus Meeting,” *Amyotrophic Lateral Sclerosis* 11 (2010): 38-45. https://dx.doi.org/10.3109/17482960903545334
- Sean Scott et al, “Design, Power, and Interpretation of Studies in the Standard Murine Model of ALS,” *Amyotrophic Lateral Sclerosis* 9 (2008): 4-15. https://dx.doi.org/10.1080/17482960701856300
- Albert C. Ludolph et al, “Guidelines for the Preclinical *in vivo* Evaluation of Pharmacological Active Drugs for ALS/MND: Report on the 142nd ENMC International Workshop,” *Amyotrophic Lateral Sclerosis* 8 (2007): 217-223. https://dx.doi.org/10.1080/17482960701292837

Clinical trials are not allowed within this funding opportunity.

For biomarker development efforts proposing to use large datasets for training predictive models, a discussion of mechanisms for addressing rigor in model design, training, and assessment should be provided. Depending upon the context, this might include algorithmic designs to avoid overfitting, saliency analysis, feature attribution, node ablation, or other alternate strategies.

Precision medicine approaches based on results from long-read sequencing and epigenetic profiling are strongly encouraged.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

3.4. Funding Details

Period of Performance: The maximum period of performance is **two** years.

Cost Cap: The application's total costs budgeted for the entire period of performance should not exceed **$840,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **two** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for one investigator to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the ALSRP Therapeutic Idea Award.

Must not be requested for:

- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOD organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - **Innovation:** Describe how the project explores a highly innovative, untested, potentially high-gain concept, theory, paradigm, and/or method that may lead to future therapeutics for ALS. Innovative uses or investigations of previously developed resources are acceptable. Research that is an incremental advance upon published data is not considered innovative.
  - **Impact:** State explicitly how the proposed work will have an impact on the development of therapeutics for ALS and on patient populations. Outline, in general terms, how the proposed research may lay the foundation for a new direction in ALS therapy development and the next steps to transition the study outcomes to therapeutic application(s).
  - **Research Strategy and Feasibility:** Explain the rationale for selecting the specific target(s) for investigation. Concisely state the project's objectives and specific aims. Describe how the proposed experiments demonstrate the testability of the hypothesis. Describe the high-risk/high-gain nature of the testable hypothesis to be investigated. If animal models are to be used, describe the selected model and its relevance to the hypothesis. Explain the feasibility of the study leading to a therapy for ALS.
  - **Biomarker Rationale:** Describe the proposed biomarker, the proposed contexts of use, and the biological rationale for the proposed biomarker, including feasibility and regulatory considerations for eventual use in ALS clinical trials. Describe the extent to which study results will be used to steer the therapeutic development process.

- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:
    - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
    - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
    - **Key Personnel Biographical Sketches: *All biographical sketches should be uploaded as a single combined file.*** Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (12-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed project in detail using the outline below.

  – **Innovation:** Describe how the project may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. For hypothesis-generating research that may be high-risk, clearly describe the potential gain and anticipated advancements in ALS therapeutic development. This may include a description of novel applications or investigations of a previously developed resource.

  – **Scientific Rationale:** Present the scientific rationale behind the proposed work. State the specific aims of the study. Explain how the novel idea is supported by sound logical reasoning and strong scientific rationale. Cite relevant published literature and, if applicable, any preliminary data (preliminary data are not required; if preliminary data are provided, the details should include statistical analysis). Applicants from outside the ALS research field are encouraged to include collaborators with the necessary relevant expertise, such as experience with ALS model systems, endpoints and pathogenic findings.

- **Study Personnel Description:** Describe the composition of the study team in enough detail to determine whether the team includes relevant subject matter expertise to accomplish the proposed work. Include the roles of individuals named in the organizational chart along with any external consultants or advisors who will provide critical guidance and input to the study team (e.g., statistician, biomarker interpretation expert, patient advocate/community partner). Early-career investigators or applicants from outside the ALS research field are encouraged to include collaborators with the necessary relevant expertise, such as experience with ALS model systems, endpoints and pathogenic findings, as part of the research team.
- **Hypothesis or Objective:** State the hypothesis(es) to be tested or the objective(s) to be reached.
- **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses (including appropriate controls) in sufficient detail for analysis.
  - Explain how the proposed tools or models are suited to, and will be used for, preclinical testing or development of therapeutics, as opposed to basic pathophysiology research.
  - Include qualitative milestones and control measures to assess the study's success and ensure progress toward the stated objectives.
  - Applications involving artificial intelligence should include details regarding the specific platforms and approaches that will be implemented.
  - If applicable, discuss how well any animal studies consider the published guidelines for working with ALS animal models and are designed to achieve the objectives, including the relevance of the model and endpoints/outcome measures to be used.
  - Address potential problem areas and present alternative methods and approaches. Because the TIA mechanism is designed to support high risk/high gain research, hypotheses may prove incorrect, but **the proposed experiments must be feasible and designed to adequately test the hypotheses. The "risk" should not be whether the experiments will work, but rather whether the novel therapeutic hypothesis is valid.** Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
- **Next Steps:** Describe the next steps to transition the study outcomes into further therapeutic application(s). Include how the project will produce the type and amount of data needed to apply for the next stage, i.e., ALSRP Therapeutic Development Award or other mechanisms to continue the advancement of the ALS therapeutic.
- **Biomarker:** Briefly introduce the biomarker and its Contexts of Use. Additional details of the marker effort should be provided in Attachment 8, Biomarker Statement.
- If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, Appendix 4, for additional considerations.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

  There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

  - **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
  - **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
  - **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. A standardized form for this information does not exist.
  - **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
  - **Letters of Support (two-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
  - **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

  Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project. Clearly define the goals of the effort/study as it relates to ALS drug or therapy discovery.
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact and Innovation:** Briefly describe how the research is innovative and/or impactful, highlighting its potential to advance future avenues of therapeutic investigation.
- **Biomarker(s):** State the biomarker to be investigated within the study.
- **Relevance to Military Health:** Briefly describe how the proposed research is relevant to Service Members, Veterans and their Families.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the goals, objectives, and rationale for the proposed research as it relates to ALS drug or therapy discovery.
- What types(s) of ALS patients will the research help, and how will it help them?
- What are the potential applications, benefits and risks of the anticipated outcomes?
- How is the proposed research innovative?
- What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?
- How is the proposed research relevant to Service Members, Veterans and their Families?

○ **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to Example: Assembling a Generic Statement of Work. Include milestones for data or research resource(s) sharing.

○ **Attachment 6: Impact Statement (one-page limit): Upload as "Impact.pdf".** Describe how the proposed work will impact development of therapeutics for ALS. Articulate a pathway to making a clinical impact for individuals with, or at risk for, ALS. Impact should address the points outlined below ***in a manner that will be readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations.

Specifically highlight how the research will achieve the following by the end of the performance period:

- Advance the development of a groundbreaking ALS therapeutic, including for specific subset populations.

- Show potential for application in the clinic and ultimate impact on ALS patient populations.
- Advance biomarkers with the potential for meaningful treatment outcomes in parallel with the main therapeutic development effort.
- Describe how knowledge, information, products, or technologies gained from the proposed research is of significance to Service Members, Veterans and/or their Families.
- If applicable, describe how the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.

Key points may be bulleted to emphasize the main study goals. Inclusion of a simple diagram of the proposed study, if plausible, is encouraged.

- **Attachment 7: Data and Research Resources Sharing Plan (one-page limit): Upload as "Sharing.pdf".** Describe how data and resources generated during the performance of the project will be shared with the research community. Describe whether the proposed plan for data sharing includes existing, publicly available, curated ALS repositories/data platforms or other resources with relevant repository parameters and mechanisms for broad access to data and samples; and whether the plan describes organizational and technical capabilities sufficient to share project data in a timely manner. *Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations).* A list of suitable resources can be found on the ALSRP web page.

  Do not submit a copy of the NIH Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

  Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available. The government reserves the right to identify repositories for submission of data for archive. Any costs associated with submission will be addressed during award negotiations. Note that this document may be used in programmatic review deliberations.

- **Attachment 8: Biomarker Statement (four-page limit): Upload as "Biomarker.pdf".** Preliminary biomarker characterization must address qualification criteria described in relevant ALS biomarker literature. See Section 3.2.1, Key Elements for the TIA, for more information on relevant ALS biomarker literature.

  Provide the following information:

  - **Biomarker(s) Description:** Describe the biomarker(s) and the theoretical or empirical basis for its potential utility. Biomarkers may reference levels of analytes in fluids or samples, radiologically measured parameters, or any other objectively measured values used to reach a single interpretation. Specify the aspect of the biomarker that is measured and the form in which it is used for biological interpretation.
  - **Purpose in ALS Drug Development:** Describe how the proposed marker(s) will demonstrate target engagement, help refine individual patient or patient subgroup selection, and/or clarify the mechanism-specific biological impact of the novel ALS therapeutic. Describe the extent to which the marker results will be used to steer the development process. Describe potential regulatory considerations for use in ALS

clinical trials. Explain how the biomarker characterization addresses qualification criteria described in relevant ALS biomarker literature.

- Describe how easily and reliably the biomarker may be implemented in eventual clinical trials of the proposed novel therapeutic, including regulatory considerations.
- ***The inclusion of a decision-tree diagram that explicitly illustrates the application of the biomarker(s) and includes the actions that would be taken based on the results is recommended.***

- **Attachment 9: Animal Research Plan (three-page limit), if applicable: Upload as "AnimalPlan.pdf".** ***Attachment 9 is only applicable and required for applications proposing animal studies.*** If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:
  - Describe consideration of the guidelines for working with ALS animal models.
  - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
  - For efficacy studies, provide the rationale for the dose and route of administration for the drug(s).
  - Summarize the procedures to be conducted. Describe how the study will be controlled.
  - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
  - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis and identification of the primary endpoint(s).
- **Attachment 10: Representations** ***(Grants.gov submissions only)*****: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 11: Suggested Intragovernmental/Intramural Budget Form** ***(if applicable)*****: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526ALSRPTIA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 ALSRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 ALSRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the Defense Health Program and the ALSRP, pre-applications will be screened based on the following criteria:

- **Innovation:** How well the project explores a highly innovative, untested, potentially high-gain concept, theory, paradigm, and/or method that may lead to future therapeutics for ALS.
- **Impact:** Whether the proposed work will have an impact on the development of therapeutics for ALS and on patient populations. Whether the proposed work may lead to new directions in ALS therapy development and includes an outline for the transition of study outcomes to therapeutic application.
- **Research Strategy and Feasibility:** How well the proposed research addresses the intent of the award mechanism. Whether the scientific rationale supports the project objectives, specific aims and feasibility. Whether the pre-application describes how the proposed experiments demonstrate the testability of the hypothesis.
- **Biomarker Rationale:** To what extent the proposed context of use and biological rationale for the proposed biomarker, including feasibility and regulatory considerations for eventual use in ALS clinical trials, are described.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Innovation**
  - How well the research introduces a new paradigm, challenges current paradigms, introduces novel concepts or agents, or exhibits other uniquely creative qualities that may lead to potential therapeutics for ALS.
  - For potentially high-risk research, how well the potential gain and anticipated advancements in ALS therapeutic development are described.
  - If applicable, how well the proposed research describes novel applications or investigations of a previously developed resource.
- **Impact**
  - To what extent the research will make a significant contribution toward the development of groundbreaking therapeutics for the intended ALS patient population, which may include specific subset populations.
  - How well the next steps for further therapeutic development are articulated, including how the project will produce the type and amount of data needed to apply for the next stage of funding.
  - Whether the knowledge, information, products, or technologies gained from the proposed research is of significance to Service Members, Veterans and/or their Families.
  - If applicable, to what extent the anticipated outcomes of the proposed study will make an impact in understanding health differences between sexes.
- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the published literature and, if applicable, any preliminary data (preliminary data are not required) and/or by logical reasoning.
  - Whether the proposed experiments and analysis are well integrated and likely to generate conclusive answers to the proposed hypotheses, whether positive or negative.
  - How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed and integrated into the project.
  - How well the studies are designed to achieve reproducible and rigorous results, the potential challenges and alternative strategies are identified, and the alternative methods and approaches are addressed.
  - Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.
  - If applicable, whether the ALS animal study (or studies) is designed to achieve the objectives, including the choice of model and incorporation of ALS model guidelines, model group size, and endpoints/outcome measures to be used.
  - For efficacy studies in animals, whether the therapeutic candidate(s)/agent(s) and route(s) of administration are justified.

- If applicable, whether the proposed ALS animal study (or studies) is designed to achieve reproducible and rigorous results, including controls, statistical methods used, sample size estimation, blinding, randomization and data handling.

- **Biomarker Statement**
  - How well the preliminary biomarker characterization considers qualification criteria described in relevant ALS biomarker literature.
  - How well theoretical arguments and/or empirical data support the utility of the proposed biomarker(s) to demonstrate target engagement, help refine individual patient or patient subgroup selection, **and/or** clarify biological impact of a potential therapeutic.
  - How well the application describes the extent to which the biomarker results will be used to steer the development process.
  - How easily and reliably the biomarker(s) could be implemented in eventual clinical trials of the proposed novel therapeutic.
- **Data and Research Resources Sharing**
  - The extent to which the application provides a clear and detailed plan for sharing data and resources generated during the project with the broader research community.
  - The extent that the proposed plan for data sharing includes existing, publicly available, curated ALS repositories/data platforms or other resources with relevant repository parameters and mechanisms for broad access to data and samples.
  - How well the plan describes whether organizational and technical capabilities are sufficient to share project data in a timely manner.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Personnel**
  - The appropriateness of the study team's expertise and the level of effort committed to ensure the successful execution of the proposed work.
  - If early-career investigators or applicants from outside the ALS research field are named as PI, whether collaborators with the necessary relevant expertise, such as experience with ALS model systems, endpoints and pathogenic findings, are included as part of the research team.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - The extent to which the scientific environment and the quality and level of institutional support are appropriate for the successful execution of the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 ALSRP, as evidenced by the following:
    - Adherence to the intent of the funding opportunity
    - Program portfolio composition
    - Relative impact and innovation, and/or military benefit

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, PIs will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information About the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review.*** Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the ALSRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, Institutional Review Board (IRB) or Ethics Committee (EC) review.

8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of pre-applications and full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- The Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- The Project Narrative is missing.
- The Budget is missing.
- The submission of an application for which a letter of invitation was not issued.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 ALSRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b)

cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the eligibility criteria.
- A clinical trial is proposed.
- The Animal Research Plan (Attachment 9) is missing, *for applications proposing animal research.*
- The invited application proposes a different research project than that described in the pre-application.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐
Attachments	
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	☐
Data and Research Resources Sharing Plan – Attachment 7, upload as "Sharing.pdf"	☐
Biomarker Statement – Attachment 8, upload as "Biomarker.pdf"	☐
Animal Research Plan – Attachment 9, upload as "AnimalPlan.pdf"	☐
Representations ***(Grants.gov submissions only)*** **– Attachment 10, upload as "RequiredReps.pdf"**	☐
Suggested Intragovernmental/Intramural Budget Form ***(if applicable)*** **– Attachment 11, upload as "IGBudget.pdf"**	☐
Additional Application Materials	
Research & Related Senior/Key Person Profile (Expanded)	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐
Research & Related Budget	☐
Project/Performance Site Location(s)	☐
Research & Related Subaward Budget Attachment(s) ***(if applicable)***	☐

Appendix 2. Acronym List

ALS	Amyotrophic Lateral Sclerosis
ALSRP	Amyotrophic Lateral Sclerosis Research Program
ARRIVE	Animal Research: Reporting of In Vivo Experiments
BEST	Biomarkers, EndpointS, and Other Tools
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FDA	U.S. Food and Drug Administration
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IND	Investigational New Drug
IRB	Institutional Review Board
LC-MS	Liquid Chromatography-Mass Spectrometry
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
NINDS	National Institute of Neurological Disorders and Stroke
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management

SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
TIA	Therapeutic Idea Award
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs